Central Retinal Vein Occlusion Market: By Treatment, By Condition, By Diagnosis, By End Users and Geography

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Central Retinal Vein Occlusion Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment (Anti-vascular Endothelial Growth Factor, Corticosteroid Drugs, Laser Retinal Photocoagulation, and Others), By Condition (Ischemic, Non-Ischemic), By Diagnosis (Optical Coherence Tomography, Fundoscopic Examination, Fluorescein Angiography, and Others), By End Users (Hospitals, Clinics, Research and Academics, Others) and Region

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Central Retinal Vein Occlusion Market was valued at US$ 3.4 billion in 2023 and is poised to grow at a CAGR of 6.2% over 2024-2030. Central retinal vein occlusion (CRVO) is a condition in which the main vein that drains blood from the retina closes off partially or completely at or proximal to the lamina cribrosa of the optic nerve, where the central vein exists in the eye, causing blurred vision, and other eye problems. Based on the treatment type, Anti–vascular endothelial growth factor is anticipated to dominate the central retinal vein occlusion market share over the forecast period.

According to a research report, globally, an estimated 2.5 million adults are affected by central retinal vein occlusion. The rise of ophthalmic disease with the increase in the elderly population will act as the central retinal vein occlusion market growth driver, whereas the high cost of treatment and side effects would be the restraining factor for the market. Investment by the market players in the treatment and diagnosis of the condition and in product development and expansion of product portfolios are opportunities for the expansion of the market.

Central Retinal Vein Occlusion Market Key Developments:

  • In Feb 2023, Kodiak Sciences completed a phase-III BEACON trial in retinal vein occlusion in the USA, Czech Republic, France, Hungary, Israel, Italy, Latvia, Poland, and Others for KSI-301, an intravitreal injection.

summary download arrow Download Free Sample

Central Retinal Vein Occlusion Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

6.2%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Central Retinal Vein Occlusion Market Dynamics

The increasing prevalence of diabetes and atherosclerosis and rising cases of patients with myeloma, lymphoma, and glaucoma are the major factors accelerating the growth of the central retinal vein occlusion market. Furthermore, there are emerging therapies including ONS-5010, KSI-301, Vabysmo, and others for retinal vein occlusion with the potential to create a positive shift in the market. Thus, the increased awareness, research, and development for eye disorders will lead to market growth within the forecast period.

Central Retinal Vein Occlusion Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 3.4 billion

Market CAGR

6.2%

By Treatment

  • Enzyme Replacement Therapy
  • Stem Cell Therapy
  • Substrate Reduction Therapy
  • Others

By Disease Type

  • Fabry Disease
  • Tay-Sachs Disease
  • Gaucher’s Disease
  • Pompe’s Disease
  • Others

By End User

  • Hospitals
  • Clinics
  • Homecare
  • Others

Key Features of the Report

  • The central retinal vein occlusion market report provides granular level information about the market size, regional market share, historic market (2019-2023) and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The global central retinal vein occlusion market size was valued at US$ 3.4 billion in 2023 and is projected to grow at a CAGR of 6.2% from 2024 to 2030.

Investment by the market players in the treatment and diagnosis of the condition and in product development and expansion of product portfolios are the key opportunities for the Central Retinal Vein Occlusion market.

The rise of ophthalmic disease with the increase in elderly population are the growth drivers in the Central Retinal Vein Occlusion market.

Allergan, Bayer AG, IRIDEX Corporation, Lumenis, Novartis AG, NIDEK CO., LTD., Roche Ltd., Regeneron Pharmaceuticals, Inc., Topcon Corporation, Merck & Co., Inc., Carl Zeiss AG, Alimera Sciences, Annexin Pharmaceuticals, and Amgen Inc. are a few companies operating in the Central Retinal Vein Occlusion market.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Central Retinal Vein Occlusion Market Introduction 
2.1.Global Central Retinal Vein Occlusion Market  - Taxonomy
2.2.Global Central Retinal Vein Occlusion Market  - Definitions
2.2.1.Treatment
2.2.2.Disease Type
2.2.3.End User
2.2.4.Region
3.Global Central Retinal Vein Occlusion Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Central Retinal Vein Occlusion Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Central Retinal Vein Occlusion Market  By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Enzyme Replacement Therapy
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Stem Cell Therapy
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Substrate Reduction Therapy
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Central Retinal Vein Occlusion Market  By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Fabry Disease
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Tay-Sachs Disease
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Gaucher’s Disease
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Pompe’s Disease
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Central Retinal Vein Occlusion Market  By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Clinics
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
8.Global Central Retinal Vein Occlusion Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Central Retinal Vein Occlusion Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Enzyme Replacement Therapy
9.1.2.Stem Cell Therapy
9.1.3.Substrate Reduction Therapy
9.1.4.Others
9.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Fabry Disease
9.2.2.Tay-Sachs Disease
9.2.3.Gaucher’s Disease
9.2.4.Pompe’s Disease
9.2.5.Others
9.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospitals
9.3.2.Clinics
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Central Retinal Vein Occlusion Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Enzyme Replacement Therapy
10.1.2.Stem Cell Therapy
10.1.3.Substrate Reduction Therapy
10.1.4.Others
10.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Fabry Disease
10.2.2.Tay-Sachs Disease
10.2.3.Gaucher’s Disease
10.2.4.Pompe’s Disease
10.2.5.Others
10.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospitals
10.3.2.Clinics
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Central Retinal Vein Occlusion Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Enzyme Replacement Therapy
11.1.2.Stem Cell Therapy
11.1.3.Substrate Reduction Therapy
11.1.4.Others
11.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Fabry Disease
11.2.2.Tay-Sachs Disease
11.2.3.Gaucher’s Disease
11.2.4.Pompe’s Disease
11.2.5.Others
11.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospitals
11.3.2.Clinics
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Central Retinal Vein Occlusion Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Enzyme Replacement Therapy
12.1.2.Stem Cell Therapy
12.1.3.Substrate Reduction Therapy
12.1.4.Others
12.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Fabry Disease
12.2.2.Tay-Sachs Disease
12.2.3.Gaucher’s Disease
12.2.4.Pompe’s Disease
12.2.5.Others
12.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospitals
12.3.2.Clinics
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Central Retinal Vein Occlusion Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Enzyme Replacement Therapy
13.1.2.Stem Cell Therapy
13.1.3.Substrate Reduction Therapy
13.1.4.Others
13.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Fabry Disease
13.2.2.Tay-Sachs Disease
13.2.3.Gaucher’s Disease
13.2.4.Pompe’s Disease
13.2.5.Others
13.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospitals
13.3.2.Clinics
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Allergan
14.2.2.Bayer AG
14.2.3.IRIDEX Corporation
14.2.4.Lumenis
14.2.5.Novartis AG
14.2.6.NIDEK CO., LTD.
14.2.7.Roche Ltd.
14.2.8.Regeneron Pharmaceuticals, Inc.
14.2.9.Topcon Corporation
14.2.10.Merck & Co., Inc.
14.2.11.Carl Zeiss AG
14.2.12.Alimera Sciences
14.2.13.Annexin Pharmaceuticals
14.2.14.Amgen Inc.
14.2.15.Bosch Healthcare Solutions GmbH
14.2.16.Baxter
14.2.17.Novartis AG
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Allergan
  • Bayer AG
  • IRIDEX Corporation
  • Lumenis
  • Novartis AG
  • NIDEK CO., LTD.
  • Roche Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Topcon Corporation
  • Merck & Co., Inc.
  • Carl Zeiss AG
  • Alimera Sciences
  • Annexin Pharmaceuticals
  • Amgen Inc.
  • Bosch Healthcare Solutions GmbH
  • Baxter
  • Novartis AG

Related Industry Reports

Chronic Refractory Gout Pharmaceuticals Market

Familial Mediterranean Fever Pharmaceuticals Market

Australia Point of Care Diagnostics Market

Aseptic Sampling Market